OCALA, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the Company’s Q3 2024 operational and financial results on Friday, November 15, 2024 at 8:30 AM ET. The call will be hosted by members of AIM’s leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conferenc ...

SINGAPORE, Oct. 15, 2024 (GLOBE NEWSWIRE) -- BitFuFu Inc., (“BitFuFu” or “the Company”) (NASDAQ: FUFU), a fast-growing digital asset mining service and world-leading cloud-mining service provider, today announced that it will attend the AIM Summit Dubai 2024, which will take place from October 21 to 22, 2024, at Jumeirah Emirates Towers. Representing BitFuFu at the event will be Ms. Calla Zhao, Chief Financial Officer of BitFuFu, and Ms. Celine Lu, Director of BitFuFu. Attendees are invited to meet the BitF ...

OCALA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. patent No. 12,102,649, covering both compositions and methods comprising the Company’s drug Ampligen® in the treatment of endometriosis, a painful chronic condition that affects nearly 10% of women of reproductive age, or approximately 6.5 million women in the United States. Endometriosis is a disease in w ...

OCALA, Fla., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM will participate in a Virtual Investor CEO Connect segment on Wednesday, October 2, 2024 at 4:00 PM ET. As part of the event, Mr. Equels will provide a brief presentation, followed by an interactive Q&A session. Investors and interested parties will have the opportunity to submit questions live during the event. Questions can ...

Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Additional commentary published discussing the potential of Ampligen and two other drugs OCALA, Fla., Aug. 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the official print publication of the data analysis from a long-term Early Access Program (“EAP”) studying the company’s drug Ampligen® (rintatolimod) for the treatment of advanced pancreatic ...

财务数据和关键指标变化 - 公司现金、现金等价物和有价证券为10.1百万美元(截至2024年6月30日) [25] - 研发费用为三个月1.1百万美元,六个月3.1百万美元(2024年6月30日),较2023年同期分别下降63.3%和38% [25] - 管理费用为三个月2.6百万美元,六个月6.4百万美元(2024年6月30日),较2023年同期分别持平和增加33.3% [26] 各条业务线数据和关键指标变化 - 公司正在推进安普利根在胰腺癌和卵巢癌等肿瘤适应症的临床试验 [14][19] - 在胰腺癌试验中,第一剂量组3例患者中有2例疾病稳定,1例轻微进展(12周时),首例患者在24周时仍保持疾病稳定 [16][17] - 在卵巢癌试验中,患者临床获益率超过60%,试验将提前结束,未来将发表相关论文 [20][21] 各个市场数据和关键指标变化 - 无相关信息 公司战略和发展方向及行业竞争 - 公司正在与阿斯利康和默克等大型制药公司合作开展临床试验 [28] - 公司认为安普利根有潜力为患者群体带来巨大价值 [27] - 公司正在与患者倡导组织合作,以更好地了解患者需求,优化后续试验设计 [23] 管理层对经营环境和未来前景的评论 - 管理层对安普利根在肿瘤适应症上的潜力表示乐观 [8][9][26][27] - 管理层认为公司有足够的现金资源支持未来关键里程碑的实现 [25] 其他重要信息 - 公司致力于提高透明度,通过"CEO角落"等平台与投资者保持沟通 [11][12] - 公司正在分析后COVID疲劳症状患者的生物标志物数据,预计9月中旬获得结果,并计划在第四季度向FDA提交初步监管方案 [23][24] 问答环节重要的提问和回答 无相关内容

– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company to host conference call and webcast today, August 16th at 8:30 AM ET OCALA, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the second quarter 2024. As previously announced, the Company will host a conference call and webcast today, Friday, August 16, 2024, at 8:30 ...

财务业绩 - 公司净亏损同比下降63%，主要原因包括收入增加、利息及其他收入增加、研发费用减少等[302] - 研发费用同比下降约1,808,000美元，主要是外包费用和临床费用的减少[310] - 一般及行政费用同比增加约41,000美元，主要是投资银行费用增加[311] 融资活动 - 公司于2024年2月16日与Streeterville签订票据购买协议，导致利息费用增加[312] - 公司通过Maxim代理在公开市场上出售总价值850万美元的普通股[330] - 公司从Atlas获得了250万美元的无担保债券融资,并建立了最高1500万美元的股权融资额度[331] - 公司与单一认可投资者完成了约2047688美元的注册直接发行和私募配售交易,发行了564.0958万股普通股及相应的认股权证[332,333] - 公司与配售代理签订了配售代理协议,配售代理将获得8%的现金佣金和部分费用报销[336] - 公司未来可能需要通过股权融资等方式筹集更多资金,但存在不确定性和潜在的股权稀释风险[337] 其他 - 公司收回2,500,000美元的董事和高管保险赔付款[306] - 公司研发和临床试验费用预计未来24个月内有足够资金支持[329] - 公司作为小报告公司无需提供市场风险的定量和定性披露[338]

OCALA, Fla., Aug. 13, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the Company’s Q2 2024 operational and financial results on Friday, August 16, 2024 at 8:30 AM ET. The call will be hosted by AIM’s Chief Executive Officer Thomas K. Equels and Scientific Officer Christopher McAleer, PhD. Interested participants and investors may access the conference call by dialing (877) 407-9219 ...

OCALA, Fla., July 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. In the CEO Corner segment, AIM Chief Executive Officer Thomas Equels provides an overview of the positive data from the Phase 1 clinical trial investigating an Ampligen-containing chemokine modulation therapy in conjunction with the chemotherapy drug paclitaxel in the treatment of early stage, triple-negativ ...